Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and Invasive Aspergillosis

Invasive Aspergillosis Clinical Trial

Official title:

An Open, Multicenter Clinical Study to Evaluate the Safety, Efficacy, and Population Pharmacokinetics of ABCD for Invasive Candidiasis and Invasive Aspergillosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04225195
• Other study ID #: CSPC/ LXMSB201901/PRO-III/A
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: January 2020
• Est. completion date: June 2022

Study information

• Verified date: December 2019
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: xiugao yang
• Phone: 86-021-60677906
• Email: yangxiugao[@]mail.ecspc.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open, multicenter clinical trial of ABCD for invasive candidiasis and invasive aspergillosis.

Description:

This study will evaluate the safety, efficacy and population pharmacokinetic characteristics of ABCD in the treatment of invasive candidiasis and invasive aspergillosis. About 60 patients with confirmed invasive candidiasis or confirmed/probable/possible invasive aspergillosis will be enrolled.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: June 2022
• Est. primary completion date: April 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Patients with confirmed invasive candidiasis or confirmed/probable/possible invasive aspergillosis;

2. Agree to use contraceptive measures from the date of signing the informed consent to 6 weeks after the end of the last medication;

3. Female subjects must meet one of the following conditions: surgical sterilization;menopause for at least 1 year;a negative result of serum/urine pregnancy test before enrollment.

4. Signed Informed Consent Form.

Exclusion Criteria:

1. Allergic to ABCD or azole antifungal drugs;

2. For IC patients, administration of more than 48 hours of systemic antifungal treatment within 96 hours before enrollment; or 1 dose of amphotericin B in 7 days;

3. For IA patients, administration of more than 96 hours of systemic antifungal therapy for this infection before enrollment, or 1 dose of amphotericin B in 7 days;

4. Patients with Candida endocarditis, osteomyelitis, arthritis, endophthalmitis, abscess of liver and/or spleen, suppurative thrombophlebitis, or central nervous system infection;

5. Patients with a history of drug abuse or drug dependence;

6. Chronic pulmonary aspergillosis (duration = 3 months), aspergilloma or allergic bronchopulmonary aspergillosis;

7. Patients are known to have mixed invasive Candida or Aspergillus infections and/or ABCD is known to be ineffective;

8. Patients with abnormal liver function;

9. Patients with reduced renal function who require or are currently undergoing hemodialysis or peritoneal dialysis;

10. Hypokalemia, which cannot be corrected before trial treatment;

11. Expected survival time is less than 2 months;

12. Patients with cardiac function of New York Heart Association(NYHA)class III/IV;

13. Positive for HIV antibody;

14. Pregnant or lactating women;

Related Conditions & MeSH terms

• Aspergillosis
• Candidiasis
• Candidiasis, Invasive
• Invasive Aspergillosis
• Invasive Candidiasis

Intervention

Drug:
• Amphotericin B cholesteryl sulfate complex for injection(ABCD)
IC patients will only receive intravenous treatment with ABCD, with the longest course of treatment up to 42 days. ABCD will be administered once a day at a dose of 3-4 mg/kg. Visit plan: screening period (D-4 to D-1), baseline period (D1), treatment period and follow-up period (14±3days after the end of the last dose of ABCD). IA patients will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. The total course of treatment should be at least 6 to 12 weeks. ABCD dosing regimen will be the same as that for IC patients. Visiting plan: screening period (D-4to D-1), baseline period (D1), treatment period and follow-up period.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients who discontinued treatment due to study drug-related adverse events or abnormal laboratory tests, Intent-to-Treat (ITT) analysis set	Number of patients who discontinued treatment due to study drug-related adverse events or abnormal laboratory tests, ITT analysis set	4-6 weeks
Primary	Overall response success rate at the end of ABCD treatment, modified ITT (mITT) analysis set	Overall response success rate at the end of ABCD treatment, m ITT analysis set	4-6 weeks
Primary	Proportion of patients who discontinued treatment due to study drug-related adverse events or abnormal laboratory tests, ITT analysis set	Proportion of patients who discontinued treatment due to study drug-related adverse events or abnormal laboratory tests, ITT analysis set	4-6 weeks
Secondary	Overall response success rate at the end of ABCD treatment, Per Protocol Set(PPS) analysis set.	Overall response success rate at the end of ABCD treatment, PPS analysis set.	4-6 weeks
Secondary	The proportion of patients with microbiologically effective outcome at the end of treatment, micro-mITT analysis set	The proportion of patients with microbiologically effective outcome at the end of treatment, micro-mITT analysis set	4-6 weeks
Secondary	30-d all-cause mortality rate after starting treatment; mITT analysis set	30-d all-cause mortality rate after starting treatment; mITT analysis set	30 days after starting treatment